Hepatitis B

Dynavax Technologies Corporation (DVAX) Is Looking at a “Long Commercial Life” Ahead for Its Just-Approved Hepatitis B Vaccine

Cowen believes Dynavax has an asset on its hands that fulfills a valuable unmet need.

Julie Lamb — November 10, 2017, 2:44 PM EDT